May 2017

  ZATA relocated to MBI’s new Gateway Park facility in Worcester, MA. The facility is located within the WPI Life Sciences & Bioengineering Center (LSBC) at Gateway Park and possess unique set-ups for the ZATA’s lab operations. The location has excellent access to Downtown Worcester and to all of New England via I-290, I-190, and the MassPike.

June 2016

Dr. Ivan B. Yanachkov joined ZATA as VP of Medical Chemistry. Before that Dr. Yanachkov held the position of VP at GLSynthesis, Inc. (Worcester, MA). His extensive experience in the design, synthesis, and testing of large numbers of drug candidates significantly strengthens ZATA’s interdisciplinary team. ZATA welcomes Dr. Yanachkov on board.

May 31, 2016

Canadian Patent Application No.: 2930562 Based on International Application No.: PCT/US2014/065367 Entitled: “AZIRIDINYL CONTAINING COMPOUNDS AND METHODS OF INACTIVATING NUCLEIC ACID MOLECULES USING THE SAME” was filed by Pepper Hamilton LLP (Boston, MA) on behalf of ZATA.

May 13, 2016

U.S. National Phase Application No.: 15/036,675 with title: “Aziridinyl Containing Compounds And Methods Of Inactivating Nucleic Acid Molecules Using Same” was filed by Pepper Hamilton LLP (Boston, MA) on behalf of ZATA.

September 2015

ZATA welcomes Dr. Boris Zavizion as its Director of biology.

Prior to joining ZATA, he held the position of Director of Biology at BioSense, Inc. (Auburn, MA).  Dr Zavizion’s background and expertise in microbiology and molecular biology are a valuable addition to ZATA’s interdisciplinary team.

September 9, 2015

ZATA has been awarded by NIH SPIR Phase II – Application title: SELF-NEUTRALIZING OLIGONUCLEOTIDES WITH ENHANCED CELLULAR”. Application ID: 5R44GM109517-03. PI – David Tabatadze, PhD.